China outpacing Europe in drug innovation and development, Pfizer executive says (opens in new tab)

submitted by China has ​become a major source of new medicines and clinical research, ‌reshaping the global pharmaceutical-industry landscape, Pfizer Chief International Commercial Officer Alexandre de Germay said at an event hosted by industry lobby group the European Federation of Pharmaceutical Industries ​and Associations (EFPIA). “Today, 40% of all clinical studies in oncology in ​the world are in China,” de Germay said. “The volume of ⁠innovation that is coming out of biotech in China i...